Cencora is advancing its strategy through acquisitions that cement its position in specialty healthcare. The MSO strategy is a natural extension of Cencora's specialty provider relationships, with acquisitions of Retina Consultants of America and OneOncology providing two platform MSOs with significant capabilities.
Cyborg Score Rationale
Cencora raised its fiscal 2026 adjusted operating income guidance to growth of 11.5 percent to 13.5 percent, demonstrating strong momentum. The company reported 12% growth in adjusted operating income and 9% increase in adjusted diluted EPS for the first quarter of fiscal 2026. However, the company has a quick ratio of 0.51 and current ratio of 0.92, indicating potential liquidity constraints.
Top Insights
The US Healthcare Solutions segment showed strong performance with 21% increase in operating income, driven by acquisitions and continued specialty growth.
The company is leveraging technology and advanced analytics to differentiate its solutions in the market, capitalizing on strong specialty pharmaceutical utilization trends.
Cencora projects revenue growth of 5% to 7% for fiscal year 2026, with expected revenue reaching $340.56 billion.
Cencora holds commanding market share alongside McKesson and Cardinal Health in the US pharmaceutical wholesale industry.
Named Competitors
McKesson — Leading pharmaceutical distributor
Cardinal Health — Major healthcare services and pharmaceutical distributor
Recent Developments
(February 2026) Raised fiscal 2026 adjusted operating income guidance to 11.5-13.5% growth from prior 8-10%.
(February 2026) Completed acquisition of majority equity interests in OneOncology, strengthening footprint in oncology-focused management services.
(December 2025) US Healthcare Solutions segment delivered 21% operating income growth driven by Retina Consultants of America acquisition.
Open the full interactive Cencora, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.